Yesterday it was reported that the Pres, Prod Dev & Med Aff & CMO of Exelixis (EXEL), Gisela Schwab, exercised options to sell 123,000 EXEL shares at $5.56 a share, for a total transaction value of $2.68M.
Following Gisela Schwab’s last EXEL Sell transaction on August 20, 2018, the stock climbed by 4.6%. This is Schwab’s first Sell trade following 3 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Exelixis’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $229 million and quarterly net profit of $360 million. In comparison, last year the company earned revenue of $120 million and had a net profit of $38.49 million. EXEL’s market cap is $6.65B and the company has a P/E ratio of 10.10. Currently, Exelixis has an average volume of 4.09M.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $31.40, reflecting a 41.1% upside.
The insider sentiment on Exelixis has been negative according to 77 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.
